Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for overuse rotator cuff tendinopathy refractory to standard therapies
2017-003099-30Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in shoulder tendinopathy and tendinosis comparing Secukinumab 300 mg s.c with Placebo s.c (2 arms). Primary endpoint: Primary WORC score at week 14. Started Oct 2017; status: terminated.
02
Drugs
secukinumab
03
Conditions
shoulder tendinopathytendinosis
Beyond the preview
Go deeper on 2017-003099-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003099-30.